Učitavanje...

Thalidomide reduces tumour necrosis factor α and interleukin 12 production in patients with chronic active Crohn's disease

Background: Thalidomide improves clinical symptoms in patients with therapy refractory Crohn's disease, as shown in two recent studies. The mechanism of this effect however is still unknown. Suppression of tumour necrosis factor α (TNF-α) by thalidomide has been suggested as a possible mechanis...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Bauditz, J, Wedel, S, Lochs, H
Format: Artigo
Jezik:Inglês
Izdano: Copyright 2002 by Gut 2002
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1773116/
https://ncbi.nlm.nih.gov/pubmed/11788559
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!